🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Granules India Limited GRANULES NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.granulesindia.com
Company Profile ↓
₹900.35
+90.61% 1Y
Mkt Cap₹22,310.40 Cr
P/E36.81
P/B4.32
Div. Yield0.20%
52W High₹900.35
52W Low₹439.35
Book Value₹205.21
EPS (TTM)₹24.46

Company Overview

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 16.0%.

Reasonable Valuation

Trades at a P/E of 36.8, below the sector median of 40.0.

Healthy Margins

Operating margin of 16.7% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.30.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹5,338.92 Cr (+19.8% YoY); net profit ₹595.02 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +19.8%, earnings +18.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 5.9%, profit CAGR 4.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:5.89%
1 Year:19.81%

Compounded Profit Growth

5 Years:4.82%
1 Year:18.64%

Stock Price Performance

1 Year:+90.61%
6 Months:+49.57%
3 Months:+37.31%
1 Month:+20.31%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹439.35 ₹900.35
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)78.72 · Overbought
Price Performance
1M+20.31%
3M+37.31%
6M+49.57%
1Y+90.61%
Valuation vs Sector

P/E of 36.81 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • RSI at 79 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
36.81
Industry PE
39.97
Forward P/E
22.96
PEG Ratio
1.00
Book Value
₹205.21
Price to Book
4.32
P/S
4.15
EV/EBITDA
19.03
Dividend Yield
0.20%

Growth (CAGR)

Revenue 5Y
5.89%
Profit 5Y
4.82%
Revenue (YoY)
19.81%
Earnings (YoY)
18.64%

Profitability & Returns

ROCE
15.98%
ROE
11.70%
ROA
7.71%
Profit Margin
11.14%
Op Margin
16.65%
Gross Margin
64.87%
EPS (Latest Qtr)
₹8.23
EPS (TTM)
₹24.46

Balance Sheet & Liquidity

Debt/Equity
0.30
Quick Ratio
1.00
Current Ratio
1.80
Debt
₹1,512.04 Cr
Total Assets
₹7,719.95 Cr
Current Assets
₹3,767.65 Cr
Working Capital
₹1,675.62 Cr

Ownership

Promoter Holding
39.31%
Chg in Prom Hold
1.29%
FII / Inst Holding
20.04%
Chg in FII Hold
-1.48%

Financial Snapshot

Enterprise Value
₹22,310.40 Cr
Total Revenue (TTM)
₹5,338.92 Cr
EBITDA
₹1,195.48 Cr
Free Cash Flow
₹235.04 Cr
Operating Cash Flow
₹793.25 Cr
Shares Outstanding
₹24.78 Cr
Gross Margin
64.87%
Payout Ratio
6.13%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GRANULES Granules India Limited NIFTY_SMALLNSEPHARMA 900.35 36.81 ₹22,310.40 Cr 0.20% 15.98% 11.70% 5.89% 4.82%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 1,196.00 Cr986.00 Cr1,189.00 Cr1,156.00 Cr1,176.00 Cr1,180.00 Cr967.00 Cr1,138.00 Cr1,196.82 Cr1,208.79 Cr1,294.67 Cr1,378.02 Cr1,457.43 Cr
Cost of Revenue --------438.38 Cr425.06 Cr444.96 Cr501.56 Cr504.12 Cr
Gross Profit --------758.45 Cr783.73 Cr849.72 Cr876.46 Cr953.31 Cr
Operating Expenses 967.00 Cr849.00 Cr977.00 Cr905.00 Cr920.00 Cr921.00 Cr763.00 Cr907.00 Cr569.59 Cr605.86 Cr643.51 Cr641.89 Cr682.96 Cr
Operating Income 179.00 Cr88.00 Cr160.00 Cr198.00 Cr203.00 Cr206.00 Cr150.00 Cr173.00 Cr188.86 Cr177.87 Cr206.21 Cr234.57 Cr270.36 Cr
EBITDA 228.00 Cr137.00 Cr213.00 Cr250.00 Cr256.00 Cr259.00 Cr203.00 Cr230.00 Cr285.03 Cr237.15 Cr277.08 Cr304.46 Cr376.79 Cr
Interest Expense 19.00 Cr22.00 Cr26.00 Cr29.00 Cr29.00 Cr27.00 Cr26.00 Cr27.00 Cr23.98 Cr23.78 Cr29.19 Cr28.69 Cr32.69 Cr
Pretax Income 164.00 Cr65.00 Cr136.00 Cr170.00 Cr176.00 Cr181.00 Cr128.00 Cr153.00 Cr197.55 Cr144.53 Cr175.87 Cr202.23 Cr262.36 Cr
Tax Provision 44.28 Cr17.55 Cr34.00 Cr44.20 Cr45.76 Cr47.06 Cr30.72 Cr35.19 Cr45.52 Cr31.89 Cr45.26 Cr52.02 Cr60.79 Cr
Net Income 120.00 Cr48.00 Cr102.00 Cr126.00 Cr130.00 Cr135.00 Cr97.00 Cr118.00 Cr152.03 Cr112.64 Cr130.61 Cr150.21 Cr201.57 Cr
Diluted EPS 4.941.984.215.185.355.564.014.856.274.645.386.198.23

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,292.00 Cr1,357.00 Cr1,411.00 Cr1,685.00 Cr2,279.00 Cr2,599.00 Cr3,238.00 Cr-4,496.34 Cr4,490.16 Cr4,455.97 Cr5,338.92 Cr
Cost of Revenue --------2,383.36 Cr2,125.79 Cr1,725.70 Cr1,875.70 Cr
Gross Profit --------2,112.98 Cr2,364.37 Cr2,730.27 Cr3,463.22 Cr
Operating Expenses 1,082.00 Cr1,081.00 Cr1,112.00 Cr1,406.00 Cr1,895.00 Cr2,073.00 Cr2,382.00 Cr-1,375.28 Cr1,704.06 Cr2,010.54 Cr2,574.22 Cr
Operating Income 157.00 Cr218.00 Cr227.00 Cr202.00 Cr279.00 Cr389.00 Cr705.00 Cr-737.70 Cr660.30 Cr719.74 Cr889.00 Cr
EBITDA 210.00 Cr276.00 Cr299.00 Cr278.00 Cr384.00 Cr526.00 Cr856.00 Cr-907.09 Cr826.32 Cr988.90 Cr1,195.48 Cr
Interest Expense 32.00 Cr37.00 Cr32.00 Cr33.00 Cr28.00 Cr27.00 Cr26.00 Cr-35.42 Cr71.76 Cr103.24 Cr114.35 Cr
Pretax Income 128.00 Cr186.00 Cr230.00 Cr196.00 Cr326.00 Cr451.00 Cr704.00 Cr-687.17 Cr547.23 Cr660.17 Cr784.98 Cr
Tax Provision 37.12 Cr61.38 Cr64.40 Cr62.72 Cr88.02 Cr117.26 Cr154.88 Cr-170.58 Cr141.92 Cr158.66 Cr189.96 Cr
Net Income 91.00 Cr123.00 Cr165.00 Cr133.00 Cr236.00 Cr335.00 Cr549.00 Cr-516.60 Cr405.31 Cr501.52 Cr595.02 Cr
Diluted EPS 4.455.687.195.229.3013.1922.18-21.0016.7220.6824.46

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,203.00 Cr1,563.00 Cr1,879.00 Cr2,670.00 Cr2,979.00 Cr3,223.00 Cr3,713.00 Cr-4,904.56 Cr5,520.98 Cr6,252.56 Cr7,719.95 Cr
Current Assets --------2,574.15 Cr2,905.05 Cr3,115.48 Cr3,767.65 Cr
Cash & Equivalents --------291.56 Cr381.10 Cr466.11 Cr880.24 Cr
Inventory --------1,149.41 Cr1,300.55 Cr1,342.82 Cr1,673.03 Cr
Receivables --------948.54 Cr985.83 Cr942.22 Cr909.37 Cr
Total Liabilities --------2,069.66 Cr2,295.44 Cr2,536.98 Cr2,634.95 Cr
Current Liabilities --------1,813.50 Cr2,082.29 Cr2,003.16 Cr2,092.03 Cr
Long Term Debt --------148.64 Cr68.97 Cr311.51 Cr297.15 Cr
Total Debt 482.00 Cr641.00 Cr656.00 Cr978.00 Cr991.00 Cr892.00 Cr849.00 Cr-1,136.23 Cr1,315.06 Cr1,454.76 Cr1,512.04 Cr
Total Equity 431.00 Cr662.00 Cr904.00 Cr1,304.00 Cr1,529.00 Cr1,843.00 Cr2,174.00 Cr-2,834.91 Cr3,225.54 Cr3,715.58 Cr5,084.99 Cr
Shares Outstanding --------24.20 Cr24.24 Cr24.25 Cr24.78 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 150.00 Cr151.00 Cr188.00 Cr-1.00 Cr262.00 Cr476.00 Cr432.00 Cr-738.75 Cr439.41 Cr866.57 Cr793.25 Cr
Investing Cash Flow -146.00 Cr-162.00 Cr-326.00 Cr-462.00 Cr-270.00 Cr-160.00 Cr-277.00 Cr--191.36 Cr-360.16 Cr-691.29 Cr-773.21 Cr
Financing Cash Flow 19.00 Cr86.00 Cr56.00 Cr529.00 Cr-17.00 Cr-213.00 Cr-299.00 Cr--440.29 Cr7.66 Cr-92.51 Cr379.29 Cr
Capital Expenditure -147.00 Cr-161.00 Cr-315.00 Cr-446.00 Cr-279.00 Cr-184.00 Cr-271.00 Cr--410.68 Cr-380.58 Cr-571.69 Cr-558.21 Cr
Free Cash Flow 3.00 Cr-10.00 Cr-127.00 Cr-447.00 Cr-17.00 Cr292.00 Cr161.00 Cr-328.07 Cr58.84 Cr294.87 Cr235.04 Cr
Net Change in Cash 24.00 Cr75.00 Cr-82.00 Cr66.00 Cr-25.00 Cr103.00 Cr-144.00 Cr-107.10 Cr86.92 Cr82.77 Cr399.33 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------47.0%52.7%61.3%64.9%
Operating Margin % 12.2%16.1%16.1%12.0%12.2%15.0%21.8%-16.4%14.7%16.2%16.7%
Net Margin % 7.0%9.1%11.7%7.9%10.4%12.9%17.0%-11.5%9.0%11.3%11.1%
ROE % 21.1%18.6%18.3%10.2%15.4%18.2%25.3%-18.2%12.6%13.5%11.7%
ROCE % --------23.9%19.2%16.9%15.8%

Shareholding Pattern

Insiders
39.31%
Institutions
20.04%
Public Float
33.01%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GRANULES

Google News Mon, 13 Jul 2026

Momentum Stocks: Welspun Corp, Oracle Financial, Star Health, Granules India hit 52-week high - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOYy1tZmJOaWF4QWx4NHN3M0p3OHloS0E5MVdYeXpmX0Nid19HMWxvanFlRjlkYm9mdEM2MHRGWWtWREFZNFhmYURtUV82RDFEWXVpd0VYZzdteFJrTEU2VWdvMVlKUXc2MUJhVXZHeENfNjhTdXZXVldrMW5aZ0M5QU9ZRlJQQWc0RUJLNH…

Google News Fri, 10 Jul 2026

GRANULES Outlook for the Week (July 13, 2026 – July 17, 2026) - Equitypandit

<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTFAyRnlweXNSZ05DRms1b2ZmRnNLMk9tUkhGN1NRSlNETW9EY1FRU1hjWUtZd211YmxnRnhmZ196R1J3TDd2T2JJOG43dHpaZ1JyUFhkSnpGTFdGbjFDX1pyTjMyb0Y2U2w3Zjlj?oc=5" target="_blank">GRANULES Outlook for th…

Google News Wed, 24 Jun 2026

Stocks To Buy Today: Kush Bohra Recommends Granules India, Genus Power And More — Check Target Price - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOVTJkRE9rS2dNRURKem8tZ0JXU1FEbDJteDRVbEZ1VkNGQ1F5dkxFa003OWhVWDdNVW1iLS0ySDA5bktqVDktZE44d1VBNGtfRkQxVl9YbzZxb3hKQzBDdE5hb0FqWE9ROElkbWZoOG9XNTZrWWRUZm9KMDVsenRTR0xiaUZ0NVA1V0RrUk…

Google News Wed, 28 Jan 2026

Granules India Limited Beat Revenue Forecasts By 7.5%: Here's What Analysts Are Forecasting Next - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxQRVdtMy15RDlxY3R6TDN0U2dxN3BacUVSdW9YS2lPNmxOU1ZKUmFnenNhdWJ2NDlqN2dISjU5SGlqOWFfVzVUdzJvTUVJb19hcXNndW8xNzZPVmxuSTNTOE5hUGl2Umx2ZHUtSl9BSFdFaF9MREt5QnFPVENmZkxFUUUzdmhxNU5SN2VMTF…

Google News Fri, 27 Mar 2026

Granules, Aurobindo Pharma among top stocks to buy today; check targets - Business Standard

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOdlM2VEpfT3l6Q09aNUFXTGdYUm5idUM0aTZCUGdOMGVmUFNYQmtReFlHUHdZc0d4SGJWNkwtenN5UWlfNmZBdzlvTlRwVzM0UG4tNExvU1gtbmh4eDFDM0ZrNVl4eVB5Y2lvbVZSSXNzc1FISW9WRzNsVlVYVnJFYzhCYkYwMmF6NHBaUz…

Google News Wed, 20 May 2026

Trade Spotlight: How should you trade Granules, Tata Motors Passenger Vehicles, CG Power, Cummins India, Hindalco, and others on May 21? - TradingView

<a href="https://news.google.com/rss/articles/CBMinAJBVV95cUxORlQ3VWNLb0YtYTdtVnNXLUp4ZUxBN0Y0cjFMbTRaUG1zN2Y3Q1ZrVEdHSjV5SVBlcldOaXlsSmxIekQ2dXB2MHR1cm14UkM0V1NybjJBMjI4X0tIenJZR1lya3RKMm1nTHF2bDNOTEJNVkQ1YlZZRTFTX2dFZ3ZUaHBwcU4tYTIyMnp0ak…

GRANULES — Frequently Asked Questions

What is the current share price of Granules India Limited (GRANULES)?

As of 2026-07-15 09:52 IST, Granules India Limited (GRANULES) trades at ₹900.35 on NSE. Its 52-week range is ₹439.35 to ₹900.35.

What is the market capitalisation of GRANULES?

Granules India Limited (GRANULES) has a market capitalisation of ₹22,310.40 Cr on NSE.

What is the P/E ratio of GRANULES?

GRANULES trades at a trailing price-to-earnings (P/E) ratio of 36.81. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 4.32.

Does GRANULES pay a dividend?

Granules India Limited (GRANULES) currently offers a dividend yield of 0.20%.

What is the return on equity (ROE) of GRANULES?

GRANULES has a return on equity (ROE) of 11.70%. Its return on capital employed (ROCE) is 15.98%.

Is GRANULES a good stock to buy?

This page provides a data-driven analysis of Granules India Limited (GRANULES), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space